


STEP-WISE APPROACH FOR TREATING MENINGITIS
A SIMPLIFIED PROTOCOL FOR EFFECTIVE TREATMENT

COMMUNITY ACQUIRED MENINGITIS (CAM)

Refers to acute inflammation of the leptomeninges and subarachnoid space, acquired outside healthcare settings, predominantly caused by bacterial pathogens. CAM presents with a spectrum of symptoms, including fever, headache, neck stiffness (classical triad),altered mental status and photophobia.



*In HIV patients consider cryptococcal meningitis & send the investigations - Serum or CSF for cryptococcal antigen

Table 02: eGFR (ml/min/1.73m²) dosing table for vancomycin.

Weight Bands	Over 90	60-89	45-59	30-44	20-29	Less than 20
More than 100	2g Twice daily	1.8g Twice daily	1g Twice daily	750mg Twice daily	1g Once daily	Seek microbiology/ nephrologist opinion
86-100	1.8g Twice daily	1.35g Twice daily	1.5g Once daily	1.25g Once daily	750mg Once daily	
65-85	1.25g Twice daily	1g Twice daily	1.25g Once daily	1g Once daily	750mg Once daily	
50-64	1g Twice daily	750mg Twice daily	1g Once daily	750mg Once daily	500mg Once daily	
49-55	750mg Twice daily	500mg Twice daily	750mg Once daily	500mg Once daily	500mg Once daily	

When to start initial maintenance dose after the loading dose?

eGFR (ml/min/1.73m²)	Over 90	60-89	45-59	30-44	20-29	Less than 20
12 hours	12 hours	12 hours	24 hours	24 hours	24 hours	Seek microbiology/ nephrologist opinion

When to take initial maintenance dose after the loading dose?

Blood for vancomycin levels should be taken immediately before the dose is due (trough level).

In patients with eGFR of 20ml/min/1.73m² or more, give the dose- do not wait for the level. Check the result before the next dose is given, and adjust dose if appropriate.

In patients with eGFR less than 20ml/min/1.73m² see below.

Twice daily doses	Take blood sample before the 4 th maintenance dose is given
Once daily doses	Take blood sample before the 2 nd maintenance dose is given

This protocol doesn't account for dosing in renal failure, pregnancy & antibiotic allergy.

HEALTHCARE ASSOCIATED VENTRICULITIS & MENINGITIS (HCAVM)

Refers to infections of the meninges or ventricular system that occur as complications of neurosurgical procedures or central nervous system devices, such as external ventricular drains (EVDs), ventriculoperitoneal (VP) shunts, or intracranial pressure monitors. These infections are typically caused by nosocomial pathogens, most commonly coagulase-negative staphylococci, Staphylococcus aureus (including MRSA), gram-negative bacilli (e.g., Pseudomonas, Acinetobacter) and occasionally fungi. The clinical presentation may be subtle due to sedation or concurrent neurological pathology. Diagnosis often relies on CSF analysis (obtained via the device or LP) & neuroimaging.

Table 01: Standard therapy for CAM and HCAVM.

	Microorganism, susceptibility	Standard therapy	Duration (Days)
	If no pathogen is isolated	ceftriaxone	minimum 10
CAM	Streptococcus pneumoniae Penicillin MIC <0.1 mcg/mL 0.1-1.0 mcg/mL >2.0 mcg/mL Cefotaxime or ceftriaxone MIC > 1.0 mg/mL	penicillin G or ampicillin ceftriaxone or cefotaxime (perform sensitivity) vancomycin plus cefotaxime or ceftriaxone vancomycin plus ceftriaxone or cefotaxime	10 to 14
	Neisseria meningitidis Penicillin MIC <0.1 mcg/mL 0.1-1.0 mcg/mL	penicillin G or ampicillin ceftriaxone or cefotaxime	07
	Haemophilus influenzae beta-Lactamase negative beta-Lactamase positive	ampicillin ceftriaxone or cefotaxime	07 to 10
	Listeria monocytogenes Streptococcus agalactiae	ampicillin or penicillin G ampicillin or penicillin G	≥21 14 to 21
	Staphylococcus epidermidis	vancomycin	14 to 28
HCAVM	Staphylococcus aureus Methicillin susceptible Methicillin resistant	flucloxacillin vancomycin	14 to 28
	Escherichia coli and other Enterobacteriaceae	cefotaxime or ceftriaxone	21
	Pseudomonas aeruginosa	ceftazidime	
	Enterococcus species Ampicillin susceptible Ampicillin resistant Ampicillin and vancomycin resistant	ampicillin plus gentamicin vancomycin plus gentamicin linezolid	

References - Sri Lanka College of Microbiologists. Empirical and prophylactic use of antimicrobials: national guidelines 2024 [Internet]. Colombo: SLCM; 2024 [cited 2025 Jun 24]. Available from: https://slmimicrobiology.lk/empirical-and-prophylactic-use-of-antimicrobials-national-guidelines-sri-lanka-2024/

Tunkel AR, van de Beek D, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis [Internet]. Arlington (VA): Infectious Diseases Society of America (IDSA); 2004 [cited 2025 Jun 24]. Available from: https://www.idsociety.org/practice-guideline/bacterial-meningitis/